glp 1 drugs in development Market Overview: GLP-1 Agonists and the Obesity Market | Blog GLP-1-based therapies for diabetes, obesity

On December 22nd, the Food and Drug Administration (FDA) approved Novo Nordisks oral semaglutide tablet, a 25 mg dose of the same active ingredient found in injectable Wegovy and Ozempic

Its effects on these diseases can be attributed to reducing aging hallmarks like senescent cells and inflammation

Therefore, when assessing the efficacy of GLP-1RA drugs, the heterogeneity in participants'ages must be considered

In a post hoc analysis of the SURPASS-1 trial involving patients with T2DM, the percentage increase in adiponectin levels from baseline ranged from 16% to 23% with tirzepatide compared to a decrease of 0.2% with placebo at week 40 (190)

It is projected to reach USD 1,062.90 billion by 2035

The SELECT cardiovascular outcomes trial established that semaglutide reduces major adverse cardiovascular events by 20%, providing a strong clinical rationale for treatment that extends beyond weight management alone